Add Yahoo as a preferred source to see more of our stories on Google. By Deena Beasley (Reuters) - Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On Tuesday, Express Scripts released its annual list of formulary exclusions, which included several drugs to treat rare diseases like hemophilia, HIV and hepatitis C. Many of these products, ...

(Reuters) - Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying ...

The digital health market continues to grow exponentially with apps that promote fitness, wellness and the prevention of chronic conditions as well as telehealth solutions and remote monitoring tools.

About eight month after its unveiling, Express Scripts has now revealed the companies and programs it is including in the inaugural cohort of its digital health formulary — the first such resource ...

Pharmacy benefit manager Express Scripts is launching a digital health formulary next year: a list of digital health tools, including smartphone apps and software-enabled medical devices, to help ...

Express Scripts has selected the first 15 technology tools to include in its new digital health formulary, which launches next month. The initial batch on the formulary—or curated list of technology- ...

Pharmacy benefit manager Express Scripts announced Dec. 12 the creation of a formulary to increase provider trust in and patient access to digital and mobile health apps and devices, including those ...

Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars with competitive net costs – as preferred products on the ...